Welcome to our dedicated page for Dalrada Financl news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financl stock.
Dalrada Financial Corporation (DFCO), now identified in company communications as Dalrada Technology Group, Inc., generates news across clean energy, semiconductor deposition technology, precision manufacturing, and health care. Its press releases highlight developments within core segments such as Dalrada Climate Technology, Deposition Technology (Deptec), and Genefic Specialty Pharmacy.
News related to clean energy and climate technology often covers contracts, distribution agreements, and facility developments involving Dalrada’s heat pump technology. Examples include agreements for heat pump installations in European light industrial facilities and a master distribution agreement in the United States that targets sales of commercial and residential heat pump units across multiple regions.
Updates from Deposition Technology (Deptec) focus on advanced thin-film deposition and semiconductor-related tools. Company announcements have detailed the availability of the proprietary Spectroptix plasma spectrometer for advance ordering, as well as the establishment of a manufacturing and R&D facility in Portland, Oregon, to support deposition technology production and sales in North America and beyond.
In the health care segment, news frequently centers on Genefic, Inc. and Genefic Specialty Pharmacy. Communications include interviews and updates that describe revenue growth, expansion of specialty pharmacy services, and the operation of licensed diagnostic laboratories and an infusion pharmacy.
Dalrada’s news flow also includes corporate and governance updates, such as changes to its board of directors, executive appointments, and the selection of independent registered public accounting firms. Together, these items provide insight into the company’s strategic direction, operational focus, and corporate evolution from Dalrada Financial Corporation (DFCO) to Dalrada Technology Group, Inc. (DHTI).
Dalrada Financial Corp. (OTCQB: DFCO) announces the appointment of Anthony Zolezzi to its Board of Directors. Zolezzi, known for his commitment to sustainability, aims to enhance Dalrada's green energy initiatives. He has a proven track record with ventures like Bubba Gump Shrimp Co. and partnerships with major brands like Walmart and PepsiCo. His experience includes promoting organic agriculture and recycling projects. CEO Brian Bonar emphasizes that Zolezzi's expertise will be vital for furthering the company's sustainability goals amid growing climate change concerns.
Dalrada Financial Corp. (OTCQB: DFCO) announced the acquisition of Pacific Stem Cells, LLC, enhancing its healthcare offerings with non-invasive therapies. This strategic move is anticipated to boost Dalrada's annualized revenue by $2.5MM over the next year. Pacific Stem Cells, recognized for its high-quality regenerative treatments, aims to address various medical conditions, including those related to aging and COVID-19. The global stem cells market is projected to reach USD 17.9 billion by 2027, presenting significant growth potential for Dalrada Health Products.
Dalrada Financial Corp. (OTCQB: DFCO) announced its acquisition of International Health Group, Inc. (IHG), a healthcare training organization. This acquisition aims to enhance healthcare staffing, especially for COVID-19 vaccination efforts in Southern California. IHG, which has trained nearly 7,000 medical professionals since 2006, is projected to generate $1MM in annual revenue within a year. CEO Brian Bonar highlighted the strategic significance of this acquisition for staffing solutions in nursing and home health. With the U.S. healthcare staffing market valued at $17 billion, this move positions Dalrada for substantial growth.
Dalrada Financial Corp. (OTC Pink: DFCO) reported a remarkable growth of 1,532% in total revenues for the fiscal year ending June 30, 2020, achieving $1,178,154 in revenues compared to $72,155 in 2019. Gross profits also rose to $552,238. The surge in performance is attributed to sales of GlanHealth's sanitizing products, Prakat Solutions' expansion in software development, and new orders from Dalrada Precision. The company aims to enhance transparency by filing periodic reports with the SEC.
Dalrada Financial Corp. (OTC Pink: DFCO) has announced that its subsidiary, Dalrada Precision, acquired a license for a green energy generator with 87% efficiency. This technology aims to meet the rising demand for affordable, clean energy. It's anticipated that integrating this generator with Likido Limited could enhance energy savings by up to $110,000 annually for a 250-room hotel. The project is currently undergoing analysis for cost modeling and manufacturing, which could significantly boost Dalrada's market position in sustainable energy solutions.
Dalrada Financial Corp. (OTC Pink: DFCO) reports a remarkable 1,602% increase in total revenues, reaching $1,228,604 for the fiscal year ending June 30, 2020, compared to $72,155 in 2019. The gross profit margin stands at 43%. However, the company incurs a net loss due to higher research and development costs and capital expenditures. Q4 2020 revenues are reported at $827,797, up from $351,324 in Q3. Growth is attributed to GlanHealth's sanitizing products and Prakat Solutions' business expansion.